Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) will likely be releasing its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Nektar Therapeutics to post earnings of ($2.07) per share and revenue of $10.27 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 12, 2026 at 5:00 PM ET.
Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) last posted its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported ($1.23) earnings per share for the quarter, topping the consensus estimate of ($1.97) by $0.74. The business had revenue of $10.13 million during the quarter, compared to the consensus estimate of $10.43 million. Nektar Therapeutics had a negative net margin of 287.84% and a negative return on equity of 37.87%. On average, analysts expect Nektar Therapeutics to post ($8.08) EPS for the current fiscal year and ($11.07) EPS for the next fiscal year.
Nektar Therapeutics Trading Up 1.5%
Nektar Therapeutics stock opened at $38.55 on Thursday. Nektar Therapeutics has a 1-year low of $33.40 and a 1-year high of $109.00. The firm has a 50-day moving average of $57.14 and a 200-day moving average of $64.51. The firm has a market cap of $1.32 billion, a P/E ratio of -5.75 and a beta of 1.26.
Insider Activity
In other news, CEO Howard Robin sold 418 shares of the stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $71.98, for a total value of $30,087.64. Following the transaction, the chief executive officer directly owned 54,627 shares of the company’s stock, valued at approximately $3,932,051.46. This represents a 0.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 2.50% of the company’s stock.
Wall Street Analyst Weigh In
A number of brokerages have recently commented on NKTR. UBS Group initiated coverage on shares of Nektar Therapeutics in a research note on Monday, October 12th. They issued a “neutral” rating and a $53.00 price target for the company. Canaccord Genuity Group started coverage on shares of Nektar Therapeutics in a research report on Wednesday, July 22nd. They set a “buy” rating and a $153.00 target price on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Nektar Therapeutics in a report on Friday, August 28th. Leerink Partners assumed coverage on shares of Nektar Therapeutics in a report on Monday, October 12th. They issued an “outperform” rating and a $130.00 price target on the stock. Finally, JPMorgan Chase & Co. started coverage on shares of Nektar Therapeutics in a research note on Friday, August 21st. They set a “neutral” rating and a $65.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $130.67.
Get Our Latest Research Report on Nektar Therapeutics
Nektar Therapeutics Company Profile
Nektar Therapeutics is a biopharmaceutical company focused on discovering and developing medicines for autoimmune, inflammatory and other serious diseases. The company uses its proprietary biologics and polymer-conjugation technologies to design therapies intended to improve immune-system regulation, drug activity and dosing convenience.
Nektar’s pipeline includes rezpegaldesleukin, an investigational treatment designed to expand regulatory T cells and potentially restore immune tolerance in conditions such as atopic dermatitis, alopecia areata and other autoimmune diseases.
Featured Stories
- Five stocks we like better than Nektar Therapeutics
- Why Rising Rates Could Break the Bull Market Before AI Spending Can Save It
- Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
- The Invisible AI Backbone: Corning’s AI Fiber Play
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
